Antisense oligonucleotides (ASOs) are synthetic, single-stranded DNA molecules that can bind to specific mRNA sequences and alter protein expression. ASO gene therapies are leading to breakthroughs in the treatment of once intractable neuromuscular disorders. In 2016, ASOs became the first FDA-approved drugs for treating spinal muscular atrophy and Duchenne muscular dystrophy. Recent trials also suggest ASOs may be effective in combating Huntington's disease, amyotrophic lateral sclerosis and hereditary transthyretin amyloidosis. This article highlights ASOs' mechanism of action, their use in treating neuromuscular disease and future obstacles the gene therapy must overcome, providing an update on the state of ASO technology.
**APPLICATIONS IN DISEASE**

**Spinal muscular atrophy**

Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by mutations in the SMN1 gene (6). SMA presents with degeneration of motor neurons, muscle atrophy and weakness. In infantile-onset, SMA typically leads to severe weakness by 6 months and respiratory failure by 2 years (7). The SMN1 gene encodes survival motor neuron (SMN), a protein necessary for motor neuron health, and mutations reduce the levels of functional SMN. The SMN2 gene can also code for SMN but due to alternative splicing, most of the gene's mRNA transcripts are lacking exon 7 and instead produce a non-functional SMN variant that is rapidly degraded (8).

Rather than attempt to treat the SMN1 mutation, researchers ingeniously targeted the alternative splicing of SMN2 using the ASO nusinersen. Nusinersen binds to a downstream intron of exon 7, modulating the splicing of SMN2's mRNA to include exon 7 and produce functional SMN (9). In a 13-month double-blind randomized controlled trial, nusinersen was intrathecally administered to 121 infants with SMA (10). The nusinersen arm of the trial had a 47% lower risk of death or use of permanent assisted ventilation, compared to the control group. In addition, 51% of the infants receiving therapy were able to reach motor milestones such as sitting upright without aid, standing and rolling. However, no infants in the control group achieved these milestones. These results led to nusinersen receiving FDA approval in late 2016 and Health Canada approval in 2017, making this ASO the first treatment capable of slowing the progression of SMA.

**Duchenne muscular dystrophy**

Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disorder that leads to the breakdown and weakness of muscle (11). DMD is caused by a mutation in the gene encoding dystrophin, a structural protein that holds the cytoskeleton and plasma membrane together. Absence or dysfunction of this protein compromises muscle stability. DMD patients usually lose the ability to walk by age 12 and experience respiratory failure in their early twenties (11). About 13% of DMD cases are specifically caused by a nonsense mutation in exon 51 where an inappropriately placed stop codon produces a truncated, dysfunctional form of dystrophin (12).

The ASO eteplirsen binds to exon 51 and stimulates its excision, allowing for production of functional, albeit slightly shortened, dystrophin (13). In a double-blind placebo-controlled trial involving 12 patients, eteplirsen was intravenously infused for 48 weeks after which muscle biopsies were taken (14). Eteplirsen increased the percentage of dystrophin-positive fibers to 52% of normal. The drug also allowed DMD patients to walk an additional 67 meters, compared to placebo, in a 6-minute walk test. Despite these modest improvements, the FDA review team recommended against approving eteplirsen, citing the small sample size and questioning whether dystrophin levels had been enhanced enough to observe a true clinical benefit (15). Controversially, the FDA's director of the Center for Drug Evaluation and Research overruled the review team and granted eteplirsen accelerated approval, making it the first drug approved in the United States to treat DMD. A larger phase III trial involving about 110 patients is currently underway and a clearer answer on eteplirsen's efficacy is expected in 2020 (16).

**Huntington's disease**

Huntington's disease (HD) is a neurodegenerative disorder caused by expansion mutations in the huntingtin gene (17). The mutation stimulates the huntingtin protein to accumulate in toxic aggregates that induce degeneration of the striatum along with progressive motor deficits and cognitive dysfunction. Many in the HD community suspect the progression of the disease may be slowed by lowering levels of the mutant huntingtin protein. Indeed, genetic mutations that naturally reduce the expression of mutant huntingtin can delay disease onset by as much as 9.3 years (18). There is currently no treatment for HD though ASO technology may soon lead to a breakthrough. In a phase I/II trial, the ASO IONIS-HTTRX was intrathecally administered over 13 weeks to 46 HD patients (19). Unlike nusinersen and eteplirsen, IONIS-HTTRX alters protein expression through RNase H mediated cleavage (20). After 3 months, there was a 40%-60% reduction of mutant huntingtin in the cerebrospinal fluid (21). Most importantly, no serious adverse events were reported, with none of the participants dropping out of the study. A phase II trial to further assess the safety and tolerability of IONIS-HTTRX in treating HD is ongoing (22).

**Amyotrophic lateral sclerosis**

Brought to prominence by Stephen Hawking, amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (23). ALS is caused by progressive degeneration of motor neurons, leading to muscle wasting, weakness and ultimately respiratory failure (23). Life expectancy after disease onset is only 3 to 5 years and current therapies have poor efficacy. Most ALS cases are sporadic, with no known cause. However, about 20% of familial ALS cases are caused by a mutation in the superoxide dismutase 1 (SOD1) gene (23).
SOD1 is an antioxidant enzyme that, when mutated, misfolds into toxic aggregates within motor neurons. There is hope that ASOs, which lower SOD1 levels may improve the disease. The feasibility of this approach was investigated in a phase I study where 32 patients with SOD1-positive ALS received intrathecal infusions of the ASO IONIS-SOD1Rx (24). Despite the ASO concentrations being too low to impact SOD1, no serious adverse events were reported. Another phase I trial investigating the safety and tolerability of the ASO is underway (25).

Hereditary transthyretin amyloidosis

Hereditary transthyretin amyloidosis (hATTR) is an autosomal dominant polyneuropathy caused by mutations in the transthyretin (TTR) encoding gene (26). Upon mutation, TTR misfolds to form insoluble amyloid fibrils that accumulate and impair various organ systems. Neurons are particularly impacted, and patients typically present with motor deficits alongside sensory and autonomic dysfunction (26). As the disease progresses, walking becomes increasingly difficult until a wheelchair is required. The average life expectancy is a mere 10 years after onset of symptoms. Since over 95% of mutant TTR is synthesized in the liver, liver transplantation is the standard of care though nerve function rarely improves after the surgery (26).

The ASO inotersen offers a far less invasive means of combating hATTR. Inotersen binds with TTR’s mRNA transcript, stimulating cleavage by RNase H and reduction of protein levels (27). The ASO was tested in a double-blind, randomized, placebo-controlled phase III trial, where 172 hATTR patients received weekly subcutaneous injections of inotersen over a 15 month period (28). Average levels of TTR fell by 74% and the rate of neuropathy progression slowed within the inotersen group. Remarkably some patients even reported reversal of their neuropathy symptoms (28). Unfortunately, there were several serious adverse events with 54% of patients in the inotersen group experiencing thrombocytopenia and one patient dying from an intracranial haemorrhage. However, no serious adverse events occurred once enhanced monitoring was implemented (28). These results culminated with inotersen receiving drug approval within the European Union in July of 2018. The drug is currently under review by the FDA and Health Canada.

FUTURE OBSTACLES

A major drawback of ASO therapies is their exorbitant price. For instance, nusinersen costs $125000 per injection (29). With the Canadian Agency for Drugs and Technology in Health recommending that health insurance only cover nusinersen for patients not requiring permanent invasive ventilation, it is pivotal that ASO therapies become less expensive (30).
Another limitation of ASOs is their poor blood-brain barrier permeability (31). Whenever the central nervous system needs to be targeted, as in the case of nusinersen and ONIS-HTTRX, intrathecal injections are necessary and this can serve as a deterrent to starting therapy. Efforts are underway to enhance ASO blood-brain barrier permeability by encapsulating the ASO in extracellular vesicles or by tagging them with cell-penetrating peptides (32). These techniques also serve to improve the bioavailability of the drug. Finally, adverse reactions are a concern for any new class of drug and though nusinersen and eteplirsen appear safe in trials, inosertem induced serious adverse events. In addition, there is always the possibility of unintended off-target genetic effects.

CONCLUSION
ASOs are revolutionizing the management of SMA and DMD, and commit to do the same for HD, ALS and hATTR. By altering the expression of genes directly implicated in disease, ASOs can target the cause of an illness far more successfully than conventional drugs. They represent a promising new frontier in genetic therapy for helping patients with previously untreatable conditions. However, challenges remain particularly in the form of excessive prices, poor blood-brain barrier permeability and coping with adverse reactions. As the technology continues to advance we can expect many more exciting breakthroughs in the treatment of neuromuscular diseases.

REFERENCES